Merck and Daiichi abandon accelerated approval plans for lung cancer ADC
Merck and Daiichi Sankyo ended plans to seek accelerated FDA approval for their antibody-drug conjugate I-DXd in lung cancer after the agency indicated existing data wouldn't support the pathway, erasing a competitive advantage over rivals.
2 sourcesCancer treatment breakthroughs
00